GlassScriptPhysician profile
Kerri L Robbins
NPI 1831333749
$1,265.11
in general payments reported to CMS, 2019-2025
13 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.31 · 2021: $36.25 · 2022: $127 · 2023: $385 · 2024: $229 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $982 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $982.21 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $473.72 | 2021-2025 | Tremfya, Remicade, Simponi |
| Sun Pharmaceutical Industries INC. | $154.30 | 2022-2025 | Winlevi, Ilumya |
| Regeneron Healthcare Solutions, INC. | $117.71 | 2022-2025 | Dupixent |
| Amgen INC. | $105.89 | 2023-2024 | Otezla |
| Abbvie INC. | $104.14 | 2022-2025 | |
| Ucb, INC. | $58.82 | 2023-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $49.12 | 2024-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.00 | 2019-2022 | |
| Incyte Corporation | $42.93 | 2023 | Opzelura |
| Galderma Laboratories, L.P. | $42.28 | 2025 | Nemluvio |
| Leo Pharma INC. | $35.92 | 2023 | Adbry |
| Organon LLC | $19.22 | 2023-2025 | Hadlima |
| Dermavant Sciences, INC. | $13.06 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerri Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.